Evidence map›Paper›PMID 34536988›Full record

ReviewTurkish journal of medical sciences2021

Pregnancy and COVID-19: prevention, vaccination, therapy, and beyond

Dilek Şahin, Atakan Tanaçan, Sophia Ne Webster, Özlem Moraloğlu Tekin

Open access · bronzeAbstract readReview
In one paragraph

Review in Turkish journal of medical sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
6.1field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 41 citations in OpenAlex.

  1. COVID-19 and Pregnancy: Key Findings.Scandinavian journal of immunology · 2026
    Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Observational
  7. An Update on COVID-19 Vaccination and Pregnancy.Journal of personalized medicine · 2023
    Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 3 countries.

Dilek ŞahinDepartment of Obstetrics and Gynecology, Ankara City Hospital, Ankara, TurkeyORCID 0000-0001-8567-9048
Atakan TanaçanDepartment of Obstetrics and Gynecology, Ankara City Hospital, Ankara, TurkeyORCID 0000-0001-8209-8248
Sophia Ne WebsterDepartment of Obstetrics and Gynecology, Newcastle-Upon-Tyne Hospital, Newcastle, United KingdomORCID 0000-0001-7965-4880
Özlem Moraloğlu TekinDepartment of Obstetrics and Gynecology, Ankara City Hospital, Ankara, TurkeyORCID 0000-0001-8167-3837
Memorial Ankara Hospital · TRAdvisory Board Company (United States) · USNorth Tyneside General Hospital · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has alarmed the world since its first emergence. As pregnancy is characterized by significant changes in cardiovascular, respiratory, endocrine, and immunological systems, there are concerns on issues like the course of disease in pregnant women, safety of medications, route of delivery and risk of obstetric complications. The aim of this review is to summarize the current literature in the management of pregnant women during the COVID-19 pandemic. Although more than 90% of pregnant women with COVID-19 recover without serious morbidity, rapid deterioration of disease and higher rates of obstetric complications may be observed. The risk of vertical transmission has not been clearly revealed yet. Decreasing the number of prenatal visits, shortening the time allocated for the examinations, active use of telemedicine services, limiting the number of persons in healthcare settings, combining prenatal tests in the same visit, restricting visitors during the visits, providing a safe environment in healthcare facilities, strict hygiene control, and providing personal protective equipment during the visits are the main strategies to control the spread of disease according to current guidelines. Although new medication alternatives are being proposed every day for the treatment of COVID-19, our knowledge about the use of most of these drugs in pregnancy is limited. Preliminary results are promising for the administration of SARS-CoV-2 vaccines in the pregnant population. Timing of delivery should be decided based on maternal health condition, accompanying obstetric complications and gestational age. Cesarean delivery should be performed for obstetric indications. Breast feeding should be encouraged as long as necessary precautions for viral transmission are taken. In conclusion, an individualized approach should be provided by a multidisciplinary team for the management of pregnant women with COVID-19 to achieve favorable outcomes.

Indexed as

COVID-19COVID-19 VaccinesFemaleHumansPandemicsPregnancyPregnancy ComplicationsSARS-CoV-2VaccinationCOVID-19 VaccinesCOVID-19obstetric complicationspregnancySARS-CoV-2vaccines

Identifiers

PMID34536988
PMCPMC8771011
OpenAlexW3200529378

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.